Lucky Core Industries Limited (LCI) — Feb 9, 2026 3:25 PM
Announcement: Corporate Briefing Session - Presentation
Key Highlights - H1 FY 2025-26
Avg Policy Rate PKR / USD LSM (YTD Nov’25) Avg Inflation
10.96% 1.3% 6% 5.6%
Operating Result of the Pharmaceuticals Business grew by Operating Result of the Animal Health Business grew by
1 2
17% mainly due to the full impact from the asset acquisition 28% driven by strong seasonal demand and post-flood
concluded with Pfizer entities in September 2024. effects.
Operating Result of the Polyester Business declined by Operating Result of the Soda Ash Business declined by 21%
3 4
79% as a result of lower volumes and margins due to due to a 63% decline in exports volumes driven by
cheaper imports. low-priced supply.
Operating Result of the Chemicals and Agri Sciences Dividend income from Lucky Core PowerGen, lower
5 6
Business declined by 21% due to disrupted crop cycles income on short term investments and bargain purchase
and lower volumes. gain on Pfizer asset acquisition booked in the SPLY.
At a Glance - H1 FY 2025-26
Unconsolidated Consolidated Financing/
Financials Financials Returns
Revenue Revenue Mkt Cap | Net Debt
PKR 56.4 Bln 9% PKR 56.3 Bln 9% PKR 133.1 Bln |
PKR 3.7 Bln
EBIT Current Ratio
EBIT
PKR 7.74 Bln 17% PKR 7.79 Bln 17% 1.5x
PAT PAT ROCE **
PKR 4.84 Bln 23% PKR 4.60 Bln 28% 35%
EPS * EPS * DPS
PKR 10.5 23% PKR 9.96 28% PKR 5.25
* EPS Restated in SPLY due to 5-1 Stock Split
** Operating Results for six months ended Dec’25 have been pro-rated to full year.
Strong Capital Structure
High cash generation, healthy payout and low gearing ratios, whilst investing in growth/expansion projects.
PKR’ m
Healthy
Returns
Balance
Sheet
Strength
Strong
Cash
Generation
R
P
P
T
E
G
C
F
C
O
A
a
o
q
e
a
r
A
R a t i
C E
T
y o u t R a t io
t a l N e t D e b t
u it y
a r in g
s h f l o w f r o m
e e C a s h f l o w
P E X
o
O
s
p e r a t io n s
F
2
Y ' 2
2 9 %
5 , 9 5
6 2 %
6 , 5 3
3 , 8 7
2 1 %
9 , 0 6
8 , 3 5
2 , 8 2
9
8
9
7
3
8
1 F Y ' 2
3 5 %
6 , 2 4
5 2 %
1 6 , 8 6
2 6 , 3 9
3 9 %
2 , 8 7
2 3 4
9 , 3 4
2
9
9
1
7
9
F Y ' 2 3
4 5 %
1 3 , 7 7 2
5 0 %
6 , 2 0 9
3 7 , 8 3 1
1 4 %
4 , 0 9 1
2 , 6 2 8
3 , 7 1 8
F Y ' 2 4
4 8 %
1 1 , 1 4 0
5 0 %
2 4 4
4 3 , 5 7 6
1 %
1 4 , 4 8 9
1 2 , 0 2 0
5 , 4 1 4
F Y ' 2 5
4 0 %
1 1 , 6 3 8
5 2 %
2 , 3 4 5
4 8 , 9 9 2
5 %
1 5 , 5 9 6
1 2 , 4 2 0
1 4 , 0 2 9
H Y 1 ' 2
3 5 %
4 , 8 4 8
5 0 %
3 , 7 3 2
5 0 , 9 7 7
7 %
4 , 0 2 1
2 , 5 8 3
2 , 4 9 6
6
**
** The Operating Results for six months ended Dec’25 have been pro-rated to full year.
Financial Performance by Business - Standalone
Chemicals &
Soda Ash Polyester Pharmaceuticals Animal Health
Agri Sciences LCI
Business Business Business Business
Business
18,512 8% 16,917 24% 11,445 10% 6,084 8% 3,453 20% 56,376 9%
I
S
N
Vs. 20,221 Vs. 22,169 Vs. 10,429 Vs. 6,616 Vs. 2,879 Vs. 62,272
Amountin PKR Mln
T 3,369 21% 263 79% 2,788 17% 764 21% 556 16% 7,740 17%
I
B
E Vs. 4,269 Vs. 1,237 Vs. 2,392 Vs. 964 Vs. 478 Vs. 9,340
Soda Ash Business - H1 FY 2025-26
All figures in PKR millions
Net Turnover Vs SPLY
Business Performance
Actual SPLY
8%
18,512 20,221
• Production capacity of 560 KTPA.
Operating Profit
Actual SPLY
21%
3,369 4,269
• Export sales volume lower by 63% due to intense
competition.
All figures in Tons
Sales Volume
Actual SPLY
6%
215K 229K
Production Volume
Actual SPLY
14%
209K 242K
Polyester Business - H1 FY 2025-26
All figures in PKR millions
Business Performance Net Turnover Vs SPLY
Actual SPLY
24%
16,917 22,169
• Production capacity of 122k tonnes.
Operating Profit
Actual SPLY
• Lower Operating Results due to lower sales volume 79%
263 1,237
and lower margins on account of cheaper imports.
All figures in Tons
Sales Volume
Actual SPLY
15%
48K 56K
Production Volume
Actual SPLY
6%
50K 54K
Pharmaceuticals Business - H1 FY 2025-26
Business Performance
All figures in PKR millions
Net Turnover Vs SPLY
Actual SPLY
10%
• Ranking improved from 19th to 16th among Pakistan’s
11,445 10,429
600+ pharmaceutical companies.
Operating Profit
Actual SPLY
• Net Turnover and Operating Result are higher due to the
17%
full impact from the asset acquisition concluded with 2,788 2,392
Pfizer entities in September 2024.
EBITDA
Actual SPLY
18%
3,058 2,586
Animal Health Business - H1 FY 2025-26
Business Performance
All figures in PKR millions
Net Turnover Vs SPLY
• Operating results for the livestock segment
Actual SPLY
improved primarily due to seasonal growth and 20%
3,453 2,879
higher demand arising from flood-spread diseases.
Operating Profit
• The poultry segment grew due to an improved
Actual SPLY
sales mix, despite industry challenges.
16%
556 478
• Construction of the greenfield Veterinary Medicine
EBITDA
Manufacturing unit is underway and expected to be
Actual SPLY
operational by year end.
14%
594 522
Chemicals and Agri Sciences Business - H1 FY 2025-26
Business Performance
All figures in PKR millions
Net Turnover Vs SPLY
Actual SPLY
8%
• Chemicals and Masterbatches segments witnessed
6,084 6,616
a modest improvement in demand, with a combined
volumetric increase of 3%.
Operating Profit
Actual SPLY
21%
• Agri Sciences Business continued to face 764 964
headwinds due to disrupted crop cycles, lower
volumes and shifting cropping preferences. EBITDA
Actual SPLY
17%
850 1,030